title: Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting.
abstract: Methotrexate (MTX) has been used in the treatment of psoriasis and other dermatological diseases for more than 50 years. However, there is limited evidence regarding its effect, dose and monitoring, and a lack of consensus regarding how the drug should be used in daily practice. Although the use of MTX is governed by guidelines, such as the European S3-Guidelines and the National Institute for Health and Care Excellence (NICE) guideline, it is important to discuss and adjust these guidelines to national standards. An expert meeting was held in Denmark at the end of 2014, in order to reach consensus regarding the use of MTX in dermatological practice in Denmark. Participants included dermatologists, hepatologists, paediatricians, clinical biochemists and a rheumatologist. Topics discussed were: liver disease monitoring, teratogenic effects of MTX, risk of cancer, and use of MTX in children. We report here the conclusions of this expert meeting regarding use of MTX in dermatological practice.
authors.affiliation: Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
authors.forename: Line
authors.initials: L
authors.lastname: Raaby
authors.forename: Claus
authors.initials: C
authors.lastname: Zachariae
authors.forename: Monika
authors.initials: M
authors.lastname: Østensen
authors.forename: Lene
authors.initials: L
authors.lastname: Heickendorff
authors.forename: Peter
authors.initials: P
authors.lastname: Thielsen
authors.forename: Henning
authors.initials: H
authors.lastname: Grønbæk
authors.forename: Lone
authors.initials: L
authors.lastname: Skov
authors.forename: Nini
authors.initials: N
authors.lastname: Kyvsgaard
authors.forename: Jakob T
authors.initials: JT
authors.lastname: Madsen
authors.forename: Michael
authors.initials: M
authors.lastname: Heidenheim
authors.forename: Anne T
authors.initials: AT
authors.lastname: Funding
authors.forename: Gitte
authors.initials: G
authors.lastname: Strauss
authors.forename: Rune
authors.initials: R
authors.lastname: Lindberg
authors.forename: Lars
authors.initials: L
authors.lastname: Iversen
mesh_terms: D000328:Adult; D000367:Age Factors; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000209:etiology; D002648:Child; D032921:Consensus; D003718:Denmark; D003880:Dermatology / Q000592:standards*; D054796:Drug Dosage Calculations; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008111:Liver Function Tests; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D009369:Neoplasms / Q000139:chemically induced / Q000175:diagnosis; D061214:Patient Safety; D011247:Pregnancy; D011248:Pregnancy Complications / Q000139:chemically induced / Q000175:diagnosis; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D008727:Methotrexate